Stock Research Monitor: BMRN, CATB, and GBT
LONDON, UK / ACCESSWIRE / July 26, 2018 / If you want a free Stock Review on BPMX sign up now at www.wallstequities.com/registration. WallStEquities.com shifts focus on the Biotechnology space, which consists of companies that are engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. Under evaluation this morning are the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), BioPharmX Corp. (NYSE American: BPMX), Catabasis Pharmaceuticals Inc. (NASDAQ: CATB), and Global Blood Therapeutics Inc. (NASDAQ: GBT). All you have to do is sign up today for this free limited time offer by clicking the link below.
San Rafael, California headquartered BioMarin Pharmaceutical Inc.'s stock finished Wednesday's session 1.17% higher at $102.18 with a total trading volume of 1.30 million shares. The Company's shares have advanced 7.69% in the past month, 25.33% over the previous three months, and 15.29% over the past year. The stock is trading above its 50-day and 200-day moving averages by 8.09% and 16.46%, respectively. Furthermore, shares of BioMarin Pharma, which develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions, have a Relative Strength Index (RSI) of 60.86.
On July 11th, 2018, BioMarin Pharma announced that Jean-Jacques Bienaimé, Chairman and CEO, will host a conference call and webcast on August 02nd, 2018, at 4:30 p.m. ET to discuss the Company's Q2 2018 financial results and provide a general business update. A live audio webcast of the conference call will be available under the investor section of the Company's website. Get the full research report on BMRN for free by clicking below at:
Shares in Menlo Park, California headquartered BioPharmX Corp. ended at $0.22, down 3.24% from the last trading session. The stock recorded a trading volume of 3.22 million shares. The Company's shares have gained 3.32% in the previous three months. The stock is trading 8.36% above its 200-day moving average. Moreover, shares of BioPharmX, which develops and commercializes novel prescription and over-the-counter products that address dermatology and women's health markets, have an RSI of 47.86.
On July 19th, 2018, BioPharmX announced that the US FDA has waived its requirement for a dermal carcinogenicity study for BPX-01, eliminating several years of non-clinical research normally required for FDA review. FDA agreed that no new useful information was likely to be gained by additional non-clinical animal studies. BPMX's complimentary research coverage is a few simple steps away at:
Cambridge, Massachusetts-based Catabasis Pharmaceuticals Inc.'s stock ended yesterday's session 4.84% higher at $0.70. A total volume of 798,475 shares was traded, which was above their three months average volume of 751,180 shares. The Company's shares are trading 41.79% below their 50-day moving average. Additionally, shares of Catabasis Pharma, which focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted linker drug discovery platform in the US, have an RSI of 26.68.
On July 09th, 2018, Catabasis Pharma announced plans for the Phase-3 POLARIS DMD trial with edasalonexent in patients with Duchenne muscular dystrophy (DMD). The Company plans to initiate the global POLARIS DMD trial in the second half of 2018, with top-line results expected in Q2 2020. Are you already registered with Wall St. Equities? Do so now for free, and get the report on CATB at:
Global Blood Therapeutics
On Wednesday, shares in South San Francisco, California headquartered Global Blood Therapeutics Inc. recorded a trading volume of 1.24 million shares, which was above their three months average volume of 1.23 million shares. The stock finished 6.55% higher at $43.10. The Company's shares have advanced 10.23% in the last month and 50.17% over the past year. The stock is trading below its 50-day moving average by 3.46%. Furthermore, shares of the Company, which engages in the discovery, development, and delivery of treatments for underserved patient communities, have an RSI of 51.72.
On June 27th, 2018, research firm H.C. Wainwright reiterated its ‘Buy' rating on the Company's stock with an increase of the target price from $73 a share to $125 a share.
On July 03rd, 2018, Global Blood Therapeutics (GBT) announced that on July 02nd, 2018, the compensation committee of its Board of Directors granted four new employees options to purchase an aggregate of 6,500 shares of the Company's common stock with a per share exercise price of $42.90, the closing trading price on the grant date, and restricted stock units for an aggregate of 4,300 shares of GBT's common stock. Aspiring Member, please take a moment to register below for your free research report on GBT at:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities